Chronic heart failure: advances in pharmacological treatment and future perspectives
Authors:
Open Access
- 11 March 2019
- journal article
- review article
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 149 (1112) , w20036
Abstract
Besides noticeable progress in device therapy during the past decade, more recent advances in the management of chronic heart failure have led to exciting new pharmacological options. Among these, the combined angiotensin II receptor/neprilysin inhibitor (ARNI) valsartan/sacubitril has already proven highly effective in heart failure with reduced ejection fraction (HFrEF), and convincing data are available regarding the cardioprotective effects of sodium-glucose-co-transporter 2 (SGLT2) inhibitors. These two treatments have earned a class I and a class II recommendation, respectively, in the European Society of Cardiology guidelines for the diagnosis and treatment of heart failure. Whereas progress with respect to heart failure with preserved ejection fraction (HFpEF) is still slow, both ARNIs and SGLT2 inhibitors hold great promise for this condition as well, and large clinical trials are currently ongoing. In addition, new diagnostic algorithms have recently been developed to improve the diagnostic accuracy for HFpEF, which will ultimately aid the search for effective therapies in future clinical trials. In this review article, these most recent advances in the diagnosis and pharmacological management of HFrEF and HFpEF are highlighted, and set-backs as well as opportunities for future developments (e.g., tafamidis for the treatment of transthyretin amyloid cardiomyopathy) are discussed.Keywords
This publication has 68 references indexed in Scilit:
- Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart FailureJACC: Heart Failure, 2018
- Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction SpectrumEuropean Journal of Heart Failure, 2018
- Effect of Sacubitril/Valsartan on Recurrent Events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)European Journal of Heart Failure, 2018
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesClinical Therapeutics, 2016
- Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection FractionJACC, 2015
- Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection FractionJAMA, 2013
- High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetesDiabetologia, 2012
- Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pigDiabetologia, 2005
- Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialThe Lancet, 2000
- Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failureMetabolism, 1991